Surrozen initiates dosing of first patient in Phase 1b trial of SZN-043

Surrozen announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis. The Phase 1b is an open-label, multi-center clinical trial that will enroll approximately 30 patients with severe alcohol-associated hepatitis. The Company plans to evaluate safety, pharmacokinetics, immunogenicity and a number of efficacy endpoints including changes in MELD score, changes in Lille score and overall survival. The MELD and Lille scores have been shown to correlate with clinical improvement and 90-day survival. “We are excited to begin enrollment in our Phase 1b clinical trial with our lead product candidate, SZN-043. The R&D organization has worked diligently to finalize regulatory approvals in multiple countries, initiate study sites and begin dosing of the first patient on schedule,” said Craig Parker, President and Chief Executive Officer of Surrozen. “We are gaining momentum in our SZN-043 clinical trial program in severe alcohol-associated hepatitis and anticipate that proof-of-concept data may be available in the first half of 2025.”